PARSIPPANY, N.J.— GlaxoSmithKline's diet pill, alli, is now back in most U.S. stores. Glaxo's innovation center for consumer products, in Parsippany, New Jersey, says the product package was redesigned to make tampering easier to spot. Before shipping alli, known chemically as orlistat, to retail stores, Glaxo launched it in mid-February through Drugstore.com and...» Read More
Arena Pharmaceuticals' new obesity drug Belviq hits the U.S. shelves today. Lonnel Coats, Eisai CEO, and Jack Lief, Arena CEO, discuss expectations for the drug.
Allergy season has been getting longer every year for 15 years, with Dr. Michael Foggs of American College of Allergy, Asthma and Immunology; and Stephen Brozak, WBB Securities, discusses the big money in the allergy business.
Andrea Sanderlin is not an actress, but her story—a horse-riding suburban mother of three accused of running a multimillion-dollar marijuana ring—sounds like a television show.
As Coca-Cola unveiled its first processing plant in Myanmar, one analyst warned that the move into frontier markets could mean emerging markets are not as attractive to multi-nationals as they once were.
Jamen Shively, a former Microsoft executive and currently CEO of Diego Pellicer, wants to build the first national marijuana store brand.
CNBC's Jackie DeAngelis reports on drug companies making headlines out of the American Society of Clinical Onocology conference. David Risinger of Morgan Stanley discusses the rise in melanoma treatments shown at this year's event.
Government officials, drug companies and medical experts, faced with outbreaks of antibiotic-resistant "superbugs", are pushing to speed up the approval of new antibiotics, the NYT reports.
A dispute within the FDA on whether to put new lung-cancer warnings on ARBs taken by millions of people is unlikely to have any significant effect on the manufacturers stocks.
A break down on the latest activity in mergers and acquisitions, with CNBC's David Faber.
Of the new drugs approved from 2004 through 2011, Quintiles was involved with 85 percent of the central nervous system drugs, 76 percent of oncology drugs and 72 percent of cardiovascular drugs. Mad Money host Jim Cramer explains why the stock is a buy.
Technical analyst Jeff Tomasulo is bearish on Pfizer after its big drop today. Fundamental analyst Pat Dorsey also isn't a buyer. (2:25)
CNBC's Andrea Day reports Swiss drug maker Novartis is disputing allegations in 2 U.S. federal lawsuits. The company is accused of wining and dining doctors.
Isis Pharmaceuticals CEO Stanley Crooke discusses his new technology Antisense and its role in helping huntington's disease.
The pharmaceutical and medical devices company reported quarterly earnings and revenue Tuesday that exceeded Wall Street's expectations as growth of newer medicines for cancer, hepatitis C and blood clots offset declining sales of its treatments for heartburn and attention deficit disorder.
The "astonishing" growth of the middle class in emerging markets is benefiting General Mills and creating jobs in the U.S., CEO Ken Powell told CNBC's "Street Signs" on Thursday.
Not every stock needs to have a "turbo-charged" growth angle to it. Mad Money host Jim Cramer says big pharma stocks have been red hot, and discusses which ones are worth owning.
Investors should always have a high yielding stock in their portfolio. Big pharma stocks tend to do better when the economy isn't doing so well, explains Mad Money host Jim Cramer. A preview of Johnson & Johnson ahead of earnings.
Johnson & Johnson just won approval for a new diabetes drug, and the stock is at an all-time high today. Anthony Butler, Barclays, offers insight.
Biotech has returned 20 percent for investors this year. Biogen IDEC CEO George Scangos, discusses the recent FDA approval of his company's drug, which is its first pill for multiple sclerosis.
The government says big pharma should not be allowed to pay generic drug makers to let them keep their costly branded drugs on the market longer, reports CNBC's Bertha Coombs.